Scholar Rock hits 3-month high as its drug helped preserve muscle in overweight patients

Scholar Rock Holding

18/06/2025 15:30

Updates

** Shares of drug developer Scholar Rock Holding Corp SRRK.O gain 17.7% to a three-month high of $36.68

** Stock set to have its best day since Nov 2024, if gains hold

** Co says its experimental drug helped patients with obesity preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's LLY.N weight-loss treatment Zepbound

** Patients receiving co's drug apitegromab with LLY's drug showed a 54.9% preservation of lean mass versus Zepbound alone over 24 weeks

** Patients receiving the combination lost more fat mass than those on LLY's tirzepatide alone

** Up to last close, stock down ~28% YTD

 (Reporting by Sriparna Roy and Padmanabhan Ananthan in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))